User Support Reference Group

Page tree

Versions Compared

Old Version 11

changes.mady.by.user Alejandro Lopez Osornio

Saved on

compared with

New Version Current

changes.mady.by.user Shane Byrnes

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Info
titleMeeting Details

Date & Time: 19th June 2025, 11am UTC


Info
titleObjectives
  • Users' discussions about the SNOMED International Drug Model and National Drug Extension Model.

Attendees:

Linda Bird Karin Drivenes Dion McMurtrie Guillermo Reynoso Michael Keary @ad Dion McMurtrie Guillermo Reynoso Venkata Aditya Parnandi Ana Paredes Benny Van Bruwaene Claudie Sombie Colin Macfarlane Eddie Mills Elisabeth Serrot Emma Melhuish Frances Ferrera Ger Gahan Hanne Johansen Ian Spiers Jaya Sonavane Jessica MacDougall

Joanna Hand Joanna Vasse Juan Ortega Callejas Julie Boutin Julien Montreuil Justin Stout Karen Rees Krista Lilly Laila Barrouhou Maria Gomez Mari­a Yunes Megan Berry Shane Byrnes Alejandro Lopez Osornio Nicola Ingram Noelle Horan Patricia Houghton Paul Wright Shane Doyle Stuart Abbott Victoire Caryn Wei Zhou Yongsheng Gao 



Info
titleZoom Link

Link: Zoom Link

Meeting ID: 85802638911

Passcode: 223446


Info
titleMeeting Recording

Link: https://snomed.zoom.us/rec/share/haDDBYEy_Zp8ry9Gq0aUj-djWHRMJYHCOpIXVR7mmuhfsL6gsK_fXUZK4RTbqv94.mfGCsVRvicjpX0Kc

Passcode: *4F0MCL!


Discussion items                                              

6
Item

Description

Mins

Owner

Notes & Actions

1Opening2 min

Alejandro Lopez Osornio Shane Byrnes 

Welcome & Notification of Recording

2Hydration Subsumption (incl. less granular Clinical Drug)50 min
@Canada
@All
  • Proposal from Canada
  • Group discussion on options


Meeting Notes

Discussion on options proposed for managing hydration subsumption:

  1. Less granular Clinical Drug - beneficial for other reasons, but likely a more complex discussion and piece of work
  2. CGI - complex in terms of modelling, and a workaround that may be replaced by a less granular clinical drug
  3. Solvate modification to substances - presents good option to manage the current challenge. Areas such as concept definitions, role chains, PAIs that are also BoSS, and challenging substances need to be worked through.

Canada will share list of c.200 known hydrated substances - to be used by group to explore approach to option 3 and help identify possible challenging cases. Examples highlighted included choral hydrate, caffeine injection, pramipexole, tacrolimus.  

3Substances Co-Ordination Update8 minAlejandro Lopez Osornio 
  • Combined substances sheet link has been updated: HERE.
  • Update on substances in multiple extensions (circa. 80)
  • Update on substances in single extensions
4AOB

Shane Byrnes 

Update from Nicki on Patch Strength representation briefing note - It has now moved to implementation.
5Topic Backlog

  • Hydration Subsumption
  • Less Granular Clinical Drug
  • Elemental Substances (Matt, AUS)
  • Dose Form Intended Site v Route of Administration (BEL)
  • Substances Co-ordination
    • Step 1: Substances in multiple extensions
    • Step 2: Substances in one extension extension
    • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)
  • Medication Stopped v Medication Discontinued (Karen, SI)
  • Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work)
  • Value range of a |Has container type| attribute (Linda, CA)
  • Drug extension MRCM attributes (CA, AUS)
  • Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 
  • Group Input on Patch Strength Representation


 

Attachments